Meridian Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Meridian Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-728	Closed	-$289K	–	142
2025 Q4	$289K	Sell	728 -100	-12%	-$44.3K	0.16%	107
2025 Q3	$378K	Buy	828 +28	+4%	+$11.4K	0.21%	88
2025 Q2	$261K	Hold	800	–	–	0.17%	102
2025 Q1	$216K	Sell	800 -100	-11%	-$25.7K	0.15%	111
2024 Q4	$212K	Hold	900	–	–	0.15%	110
2024 Q3	$248K	Hold	900	–	–	0.17%	111
2024 Q2	$219K	Buy	+900	New	+$142K	0.16%	117
2023 Q3	–	Sell	-1,234	Closed	-$234K	–	95
2023 Q2	$234K	Hold	1,234	–	–	0.21%	87
2023 Q1	$247K	Buy	+1,234	New	+$259K	0.24%	82

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meridian Financial's ALNY Position: Q1 2026 in Review

Meridian Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 728 shares — an estimated $289K sold.

Meridian Financial first reported a position in ALNY in Q1 2023 and held it in 9 quarters. The position peaked at $378K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Meridian Financial reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Meridian Financial sold 728 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $289K.
Meridian Financial first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 9 quarters.
Meridian Financial's Alnylam Pharmaceuticals position peaked at $378K in Q3 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Meridian Financial's 13F filing for Q1 2026, filed 21 Apr 2026.